Ποια είναι η τιμή για Algorae Pharmaceuticals Limited (1AI)

Η τιμή για Algorae Pharmaceuticals Limited (1AI) είναι $0.00775813

Ποια είναι η κεφαλαιοποίηση αγοράς για Algorae Pharmaceuticals Limited (1AI)

Η κεφαλαιοποίηση αγοράς για Algorae Pharmaceuticals Limited (1AI) είναι $15.73M

Algorae Pharmaceuticals Limited (1AI) Διαίρεση Μετοχών

Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.